WO2021137665A1 - Composé dérivé de 1,2,3-triazole utilisé en tant qu'inhibiteur de hsp90, et son utilisation - Google Patents

Composé dérivé de 1,2,3-triazole utilisé en tant qu'inhibiteur de hsp90, et son utilisation Download PDF

Info

Publication number
WO2021137665A1
WO2021137665A1 PCT/KR2020/095153 KR2020095153W WO2021137665A1 WO 2021137665 A1 WO2021137665 A1 WO 2021137665A1 KR 2020095153 W KR2020095153 W KR 2020095153W WO 2021137665 A1 WO2021137665 A1 WO 2021137665A1
Authority
WO
WIPO (PCT)
Prior art keywords
triazol
ethyl
dihydroxyphenyl
nmr
mhz
Prior art date
Application number
PCT/KR2020/095153
Other languages
English (en)
Korean (ko)
Inventor
류재상
이소윤
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190178450A external-priority patent/KR102406248B1/ko
Priority claimed from KR1020190178332A external-priority patent/KR102406246B1/ko
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Publication of WO2021137665A1 publication Critical patent/WO2021137665A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne : un composé dérivé de 1,2,3-triazole ayant une activité inhibitrice de la protéine de choc thermique 90 (HSP90), un isomère optique, et un sel pharmaceutiquement acceptable de celui-ci ; ainsi qu'une utilisation correspondante pour préparer un médicament thérapeutique ; une méthode de traitement l'utilisant ; une composition pharmaceutique le contenant ; et un procédé de préparation associé. Le composé représenté par la formule chimique I, l'isomère optique, ou le sel pharmaceutiquement acceptable de celui-ci, selon la présente invention peut inhiber de manière sélective la HSP90 ce qui permet d'obtenir un excellent effet de prévention ou de traitement d'une maladie associée à l'activité de HSP90.
PCT/KR2020/095153 2019-12-30 2020-12-29 Composé dérivé de 1,2,3-triazole utilisé en tant qu'inhibiteur de hsp90, et son utilisation WO2021137665A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2019-0178450 2019-12-30
KR10-2019-0178332 2019-12-30
KR1020190178450A KR102406248B1 (ko) 2019-12-30 2019-12-30 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
KR1020190178332A KR102406246B1 (ko) 2019-12-30 2019-12-30 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도

Publications (1)

Publication Number Publication Date
WO2021137665A1 true WO2021137665A1 (fr) 2021-07-08

Family

ID=76686961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/095153 WO2021137665A1 (fr) 2019-12-30 2020-12-29 Composé dérivé de 1,2,3-triazole utilisé en tant qu'inhibiteur de hsp90, et son utilisation

Country Status (1)

Country Link
WO (1) WO2021137665A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114671861A (zh) * 2022-04-12 2022-06-28 安徽医科大学 一种汉黄芩素衍生物及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013712A1 (en) * 2001-04-30 2003-01-16 Tullis Joshua Spector Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US20030100558A1 (en) * 2001-04-30 2003-05-29 Tullis Joshua Spector Triazole compounds useful in treating diseases associated with unwanted cytokine activity
KR20090023614A (ko) * 2006-05-18 2009-03-05 메르크 파텐트 게엠베하 트리아졸 유도체 ⅱ
US20140329812A1 (en) * 2010-12-20 2014-11-06 Sigma-Tau Research Switzerland S.A. Aryl triazole compounds with antitumoural activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013712A1 (en) * 2001-04-30 2003-01-16 Tullis Joshua Spector Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US20030100558A1 (en) * 2001-04-30 2003-05-29 Tullis Joshua Spector Triazole compounds useful in treating diseases associated with unwanted cytokine activity
KR20090023614A (ko) * 2006-05-18 2009-03-05 메르크 파텐트 게엠베하 트리아졸 유도체 ⅱ
US20140329812A1 (en) * 2010-12-20 2014-11-06 Sigma-Tau Research Switzerland S.A. Aryl triazole compounds with antitumoural activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI SHUANG-JUN; LIU QIAN; HE XIAO-BIN; LIU JIN-PING; LIU XIAO-LIU; HU JIE; TANG ZHI-PENG; PENG QING-YUN; CUI LIAN-JIE; ZHANG HUA-NI: "Pyrola incarnata demonstrates neuroprotective effects against β-amyloid-induced memory impairment in mice", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 30, no. 2, 4 December 2019 (2019-12-04), XP086033983, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2019.126858 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114671861A (zh) * 2022-04-12 2022-06-28 安徽医科大学 一种汉黄芩素衍生物及其制备方法与应用
CN114671861B (zh) * 2022-04-12 2023-11-24 安徽医科大学 一种汉黄芩素衍生物及其制备方法与应用

Similar Documents

Publication Publication Date Title
WO2011043568A2 (fr) Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
WO2017188694A1 (fr) Composé hétéroaryle comprenant de l'azote et son utilisation
AU2019381113B2 (en) Novel compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof
WO2018139903A1 (fr) Composé pyrimidine et son utilisation pharmaceutique
WO2017142325A1 (fr) Nouveau composé thiophène substitué en 2,3,5 utilisé en tant qu'inhibiteur de la protéine kinase
WO2014109530A1 (fr) Dérivé 2-(phényléthynyl)thiéno[3,4-b]pyrazine, et composition pharmaceutique comprenant ce dérivé et destinée à la prévention ou au traitement du cancer
AU2019217094B2 (en) Compounds for inhibiting TNIK and medical uses thereof
WO2012115479A2 (fr) Dérivés de diaminopyrimidine et leurs procédés de préparation
WO2020096372A1 (fr) Nouveau dérivé de pipéridine-2,6-dione et utilisation associée
WO2019074241A1 (fr) Inhibiteur de l'interaction entre pd-1 et pd-l1, comprenant un dérivé de phénylacétylène
AU2021226297B2 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2021137665A1 (fr) Composé dérivé de 1,2,3-triazole utilisé en tant qu'inhibiteur de hsp90, et son utilisation
WO2015060613A1 (fr) Nouveau dérivé oxodihydropyridinecarbohydrazide antifongique
WO2016006975A2 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2018151562A9 (fr) Nouveau dérivé de benzimidazole présentant une activité inhibitrice de la jnk et son utilisation
WO2019235879A1 (fr) Composition pour prévenir ou traiter le cancer, contenant un nouvel inhibiteur de mtor
WO2014065575A1 (fr) Dérivé de 4,5-dihydro-1h-pyrazole ou ses sels et composition pharmaceutique les comprenant
WO2020022787A1 (fr) Nouveau dérivé d'imidazole présentant une activité inhibitrice de jnk et composition pharmaceutique le comprenant
WO2010032986A2 (fr) Nouveaux dérivés de 5-(4-aminophenyl)-isoquinoline, leurs sels pharmaceutiquement acceptables, procédé de production associé et composition contenant les dérivés comme principe actif pour la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité de la kinase raf
WO2022086110A1 (fr) Dérivé de thiobenzimidazole ou sel pharmaceutiquement acceptable de celui-ci, et leur utilisation
WO2015016511A1 (fr) Nouveau dérivé de biphényle, et son procédé de préparation
WO2012157900A2 (fr) Précurseur marqué au 18-f pour substances radioactives à usage médical utilisées en tomographie par émission de positons et son procédé de préparation
WO2023054759A1 (fr) Dérivé de 2-aminoquinazoline et composition antivirale le comprenant
WO2018021762A1 (fr) Nouveau composé, son procédé de préparation, et composition pharmaceutique le contenant
WO2024019562A1 (fr) Composé hétérobicyclique et composition pharmaceutique le comprenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20910161

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20910161

Country of ref document: EP

Kind code of ref document: A1